RecruitingPHASE1, PHASE2NCT05667506
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Juventas Cell Therapy Ltd.
- Principal Investigator
- Xiaofan Zhu, M.D, MDInstitute of Hematology & Blood Diseases Hospital, China
- Intervention
- single dose of CNCT19(biological)
- Enrollment
- 47 enrolled
- Eligibility
- 3-18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (9)
- The Second Hospital of Anhui Medical University, Hefei, Anhui, China
- Children's Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
- Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China
- Nanfang Hospital, Guangzhou, Guangdong, China
- Union Hospital Tongji Medical College Huazhong University of Science of Technology, Wuhan, Hubei, China
- Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
- The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
- The First Affilicated Hospital of Nanchang University, Nanchang, Jiangxi, China
- Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05667506 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07328503CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- ENROLLING BY INVITATIONNCT07515430The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic LeukemiaSun Yat-sen University